3 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow Step Pharma, SAS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial STP938 - Essential Thrombocythaemia | Phase 2 | Recruiting | Step Pharma, SAS | 50 | 2025-06-18 | 2026-06-16 |
| Study of STP938 (Dencatistat) in Advanced Solid Tumours STP938 - Solid Tumor | Phase 1 | Recruiting | Step Pharma, SAS | 70 | 2024-08-02 | 2026-06-16 |
| A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas STP938 - Lymphoma, B-Cell, Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | Step Pharma, SAS | 180 | 2022-08-03 | 2026-06-16 |
Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Thrombocythemia, Essential (1)
France (3) · United Kingdom (3) · United States (2)
Maureen Higgins (3)